Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Biotech-focused investment firm Frazier Life Sciences launched Callio Therapeutics, a cancer treatment startup with ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

In the US, Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation work together to develop and co-promote Xolair. Food allergies have been on the rise for the past 20 years.

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...